
Verastem (VSTM) Stock Forecast & Price Target
Verastem (VSTM) Analyst Ratings
Bulls say
Verastem is viewed positively because its approved AVMAPKI FAKZYNJA co-pack is already generating meaningful commercial traction, with 3Q26 revenue of $24.0M, up 114% Y/Y, and strong refill growth that suggests durable demand even as new patient starts were seasonally softer. The investment case is further strengthened by a well-funded balance sheet, with pro forma cash of $422.8M expected to support operations into 1H28, while the pipeline offers multiple value-driving shots on goal through VS-7375, including a 41% confirmed ORR in 22 previously treated PDAC patients and a 67% six-month PFS landmark. Despite competitive and timing risks, the company’s RAF/MEK and FAK biology, improving safety profile, and several expected data readouts in early 2027 support a favorable long-term fundamental outlook.
Bears say
Verastem is viewed negatively because its lead asset Avmapki Fakzynja lacks sizable, definitive randomized data, leaving commercial adoption and payer confidence uncertain despite the company’s late-stage oncology focus. The downside case suggests that if traction, efficacy, or safety disappoints, VSTM could trade near its net cash position with minimal pipeline value, underscoring how little fundamental support exists beyond the program itself. Additional pressure comes from the small LGSOC addressable population, potential difficulty enrolling patients, competitive intensity that could limit launch uptake, and early-stage expansion assets like G12D that remain unproven and in competitive spaces.
This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Verastem (VSTM) Forecast
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares